Bristol Myers Squibb exec on the company’s growth in Seattle and beating cancer with immune cells

Since acquiring Celgene and its Seattle operations a couple years ago, Bristol Meyers Squibb (BMS) has been growing its presence in the Seattle area. Now, BMS has more than 150 open positions in the region.

The Seattle location is dedicated to developing therapies for blood cancers with Breyanzi and Abecma, its latest “CAR-T” therapies.

READ THE STORY at GeekWire »